Vaccine Treatment of Typhoid
نویسندگان
چکیده
the literature. Price, in the Lancet for December 1934, quotes the results of Uroiste of Montevideo and Stejskal of Vienna. These workers used carefully-standardized triple typhoid vaccine intravenously, to produce the shock. Triple vaccine, by virtue of its specificity, produces a more defined and uniform reaction than other foreign proteins or nonspecific vaccines. Being impressed by the successful results obtained by the above workers, we have treated, since June 1935, almost every case of typhoid fever which has come to the Krishnarajendra Hospital with triple vaccine. The advantages of this method of treatment
منابع مشابه
Public health round-up
WHO has prequalified the first conjugate vaccine to prevent typhoid fever. The vaccine is Typbar-TCV® developed by Indian pharmaceutical company Bharat Biotech. The vaccine confers long-lasting immunity, requires only one dose and can be given to children as young as six months through routine childhood immunization programmes. Other typhoid vaccines are recommended for children over 2 years of...
متن کاملIndian Vi conjugate typhoid vaccine: misleading claims.
447 VOLUME 47__MAY 17, 2010 I refer to the article “Vi conjugate Typhoid Vaccine” written by Garg SP(1) on behalf of the manufacturer of Peda TyphTM in response to my previous article on the same subject(2). The author states that “this novel vaccine has been found to be safe and effective in inducing very high levels of immune response (>90%) in infants, young children and adults”, and goes fu...
متن کاملEffectiveness of typhoid vaccination in US travelers.
Typhoid vaccination is recommended in the United States before travel to countries where typhoid fever is endemic, though little information is available on its effectiveness in travelers. We estimated typhoid vaccination effectiveness (VE) by comparing vaccination status in cases of typhoid fever and paratyphoid fever (Salmonella Paratyphi A infection, against which typhoid vaccine offers no p...
متن کاملTyphoid vaccine development with a human challenge model
Experimental human typhoid fever challenge was first described in 1896 by Wright, who vaccinated two men against typhoid fever and challenged one with what was then known as Salmonella typhosa. While challenge models are sometimes controversial, they offer enormous potential to study the pathogenesis of disease and to accelerate vaccine development, particularly in humanrestricted pathogens suc...
متن کاملEfficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial
BACKGROUND Salmonella enterica serovar Typhi (S Typhi) is responsible for an estimated 20 million infections and 200 000 deaths each year in resource poor regions of the world. Capsular Vi-polysaccharide-protein conjugate vaccines (Vi-conjugate vaccines) are immunogenic and can be used from infancy but there are no efficacy data for the leading candidate vaccine being considered for widespread ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 71 شماره
صفحات -
تاریخ انتشار 1936